Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Transplant Proc ; 40(4): 1140-4, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18555134

RESUMO

This study was performed to determine the safety and tolerability of injecting autologous bone marrow stem cells (BMC) (CD34+) into four patients with liver insufficiency. The study was based on the hypothesis that the CD34+ cell population in granulocyte colony stimulating factor (G-CSF) mobilized blood and autologous bone marrow contains a subpopulation of cells with the potential for regenerating damaged tissue. We separated the CD34+ stem cell population from the bone marrow. The potential of the BMC to differentiate into hepatocytes and other cell lineages has already been reported. Several reports have also demonstrated the plasticity of hematopoietic stem cells to differentiate into hepatocytes. Recently Sakaida demonstrated reduction in fibrosis in chemically induced liver cirrhosis following BMC transplantation. From a therapeutic point of view, chronic liver cirrhosis is one of the targets for BMC transplantation. In this condition, there is excessive deposition of extracellular matrix and hepatocyte necrosis. Encouraged by this evidence that the CD34+ cell population contains cells with the potential to form hepatocyte-like elements, four patients with liver insufficiency were given G-CSF to mobilize stem cells. CD34+ cells (0.1 x 10(8)) were injected into the hepatic artery. No complications or specific side effects related to the procedure were observed; four patients showed improvements in serum albumin, bilirubin and ALT after one month from the cell infusion.


Assuntos
Transplante de Medula Óssea , Falência Hepática/cirurgia , Segurança , Transplante de Células-Tronco , Adulto , Diferenciação Celular , Doença Crônica , Feminino , Citometria de Fluxo , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Mobilização de Células-Tronco Hematopoéticas/métodos , Artéria Hepática , Hepatócitos/citologia , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Transplante Autólogo , Resultado do Tratamento
2.
Transplant Proc ; 40(4): 1148-50, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18555136

RESUMO

Crigler-Najjar Syndrome (CNS) is characterized by mild, chronic unconjugated hyperbilirubinemia resulting from an autosomal-recessive inherited deficiency of hepatic uridine/diphosphoglucuronate-glucuronosyl transferase 1Al since birth. Herein we have reported a confirmed case of CNS type 1 in a 2-year-old girl with an unconjugated hyperbilirubinemia (>30 mg/dL) treated by hepatic progenitor cell infusion through the hepatic artery. No procedure-related complications were encountered. No kernicterus was observed. The total bilirubin started falling at 10 days after cell infusion. Two months after cell infusion the bilirubin fell from 29.0 to 16 mg/dL, with the conjugated bilirubin increasing approximately fivefold, the unconjugated bilirubin decreasing nearly twofold, and the SGPT also decreasing from 210 U/L to 64 U/L. This study demonstrated the efficacy of hepatic progenitor cells to manage hyperbilirubinemia in these patients. As the procedure is simple and the patient has tolerated the cell therapy, infusion can be repeated as required to manage hyperbilirubinemia, which often causes lethal kernicterus. This study was developed to assess the safety, feasibility, and efficacy of hepatic progenitor cell transplantation in a child with CNS type 1.


Assuntos
Síndrome de Crigler-Najjar/cirurgia , Hepatócitos/transplante , Hiperbilirrubinemia/cirurgia , Transplante de Células-Tronco/métodos , Animais , Bilirrubina/sangue , Pré-Escolar , Síndrome de Crigler-Najjar/sangue , Síndrome de Crigler-Najjar/genética , Modelos Animais de Doenças , Feminino , Transplante de Tecido Fetal , Glucuronosiltransferase/genética , Artéria Hepática , Humanos , Hiperbilirrubinemia/sangue , Hiperbilirrubinemia/genética , Reação em Cadeia da Polimerase
3.
Transplant Proc ; 40(4): 1153-5, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18555137

RESUMO

Cholangiodestruction of bile ducts leads to biliary atresia, a rare disease characterized by intrahepatic and extrahepatic biliary inflammation. If the intrahepatic biliary tree is unaffected, surgical reconstruction by the Kasai procedure of hepatoportoenterostomy of the extra hepatic biliary tract is possible. Untreated, this condition leads to cirrhosis and death within the first year of the life. If the atresia is complete, liver transplantation is the only option. As a result of the shortage of donor livers, hepatocytes have been infused over the past two decades, providing proof of the concept that cell therapy can be effective for the treatment of liver diseases. In the present study, we report a confirmed case of a girl of 1 year of age with increased bilirubin of 28.5 mg/dL and pediatric end-stage liver disease score 20. Biochemical liver function tests showed cholestasis (elevated cholesterol and gamma-GTs) and increased ALT, total bilirubin, conjugated bilirubin, and ALP. The patient was treated with hepatic progenitor cell infusion through the hepatic artery. The total bilirubin and conjugated bilirubin started decreasing during the first month after cell infusion. The level of total bilirubin maintained a threefold decrease after months of cell infusion. The conjugated bilirubin was 16.35 mg/dL before cell infusion, decreasing to eightfold after cell infusion. After 2 months of cell infusion, hepatobiliary scintigraphy showed increased liver cell function. This case demonstrated the efficacy and functionality of hepatic progenitor cells for the management of biliary atresia. Further, as there was a decrease in serum bilirubin, it showed that there was some percentage of the engraftment of the infused cells. As the procedure is simple and the patient has tolerated the infusion therapy, it might be repeated to manage biliary atresia.


Assuntos
Transplante de Tecido Fetal/métodos , Artéria Hepática , Hepatócitos/transplante , Hiperbilirrubinemia/cirurgia , Transplante de Células-Tronco/métodos , Alanina Transaminase/sangue , Bilirrubina/sangue , Feminino , Humanos , Hiperbilirrubinemia/sangue , Hiperbilirrubinemia/enzimologia , Lactente , Fígado/enzimologia , Testes de Função Hepática
4.
Transplant Proc ; 39(3): 694-9, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17445575

RESUMO

Stem cell research is a new field that is advancing at an incredible pace with new discoveries being reported from all over the world. Scientists have for years looked for ways to use stem cells to replace cells and tissues that are damaged or diseased. Stem cells are the foundation cells for every organ, tissue, and cell in the body. Stem cells are undifferentiated, "blank" cells that do not yet have a specific function. Under proper conditions, stem cells begin to develop into specialized tissues and organs. They are self-sustaining and can replicate themselves for long periods of time. Embryonic stem cells are pluripotent cells, isolated from the inner cell mass of the blastocyst-stage mammalian embryo. They have the ability to differentiate into several somatic or somatic-like functional cells such as neurons, hepatocytes, cardiomyocytes, and others. Adult stem cells are specialized cells found within many tissues of the body where they function in tissue homeostasis and repair. They are precursor cells capable of differentiation into several different cells. The knowledge of stem cells from various sources offered a new hope for the treatment of various diseases.


Assuntos
Transplante de Células-Tronco/tendências , Adulto , Animais , Diabetes Mellitus/terapia , Células-Tronco Embrionárias/citologia , Cardiopatias/terapia , Humanos , Fígado/citologia , Mesoderma/citologia , Modelos Animais , Modelos Biológicos , Doenças do Sistema Nervoso/terapia , Transplante de Células-Tronco/etnologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...